Neurodegenerative R&D's Harsh Reality: Alector's Collapse vs. Ionis's Resilience Amid Partner Exits

Related Articles

Rackspace's AI Ambition Collides with a Harsh Financial Reality

2 weeks ago

What Triggered GRAIL's Recent Stock Collapse

1 months ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

4 months ago

Consumer Resilience vs. Retail Headwinds: Navigating Discretionary and Essential Goods Stocks

5 months ago

Category

You may also like

Stock News•1 week ago

Ionis Pharmaceuticals: The Heartbreak Is Priced In

Ionis Pharmaceuticals fell sharply after ATTR-CM and tominersen setbacks, but core assets remain intact. Tryngolza leads value with strong sHTG data; $1.9B liquidity supports a path to 2028 breakeven.

IONS

Share

Stock News•2 weeks ago

Alector and GSK partnership to end after dementia, Alzheimer's drug failures

Alector's neuroscience collaboration with GSK ended after two experimental antibody drugs failed in clinical trials. The termination removes a key partnership and potential milestone revenue for Alect...

ALEC

Share

Stock News•3 weeks ago

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense's Phase 2b ALS study met its primary endpoint, showing a statistically significant reduction of TDP-43, a pathological hallmark present in >97% of ALS cases.

NRSN

Share

News•1 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Pharmaceutical companies are testing new methods to bypass the blood-brain barrier for Alzheimer's treatments. Results from these delivery initiatives are expected to emerge throughout this year, pote...

Share